F13A1 and glioblastoma: Secondly, we need to develop effective F13A1 inhibitors to block its mediated immunosuppressive effects, or enhance the efficacy of immunotherapy by combining immunotherapy drugs with F13A1 inhibitors, and evaluate their safety and effectiveness in the treatment of GBM.